摘要
目的评价对比厄洛替尼、帕妥株单抗单药及联合用药对人非小细胞肺癌、乳腺癌瘤细胞株疗效。方法nu/nu裸鼠90只,分别种植人非小细胞肺癌细胞株Calu-3、QG56、乳癌细胞株KPL-4各30只。经过2-3W,肺癌荷瘤鼠平均瘤体积约100mm2、乳癌荷瘤鼠平均瘤体积50mm2时,开始给药。3种肿瘤小鼠分别口服厄洛替尼(50mg/kg/d)和腹腔注射帕妥株单抗(负荷量12mg/kg,随后每周注入6mg/kg,)及二者联用。培养特定天数后用测径器分析瘤体大小、生化分析仪检测血清肿瘤标示物(肺癌:Cyfra21.1,乳腺癌:sHER2)、血浆纤维蛋白原和D-二聚体水平,每组有未经治疗的荷瘤小鼠做空白对照。结果厄洛替尼和帕妥株单抗处理组比对照组肿瘤体积明显减小(p<0.05或0.01),二者合用效果更明显。厄洛替尼或帕妥株单抗处理组,肺癌血清Cyfra21.1含量和乳腺癌血清sHER2含量均比对照组低。厄洛替尼和帕妥珠单抗均能抑制血浆D-二聚体和纤维蛋白原水平,且二者联用时血浆D-二聚体和纤维蛋白原水平更低。结论厄洛替尼和帕妥株单抗对移植到小鼠的人瘤细胞均有抑制作用,两药合用时效果更好。
Objective To investigate the therapeutic effects of elotinib and pertuzum amtibody（Ab） on human non-small cell lung cancer and breast cancer respectively. Method Human non-small cell lung cancer and breast cancer tumor bearing mice（transplanted with Calu-3,QG56,KPL-4 cell strain） were treated with erlotinib or pertuzum Ab respectively or together. The volume of tumor size,the contents of serum tumor marker（Cyfra21.1 for lung cancer and sliER for breast cander）and plasma fibrinogen and D-dimer in serum were determined after culturing for some period. Result The tumor volume in tumor-bearing mice treated with elotinib or pertuzum Ab was smaller than that in tumor control, serum tumor marker（Cyfra21, 1,sHER2）and D-dimer and fibrinogen levels in serum were lower compared with tumor control, with better therapeutic effect while elotinib and pertuzum Ab were combined. Conclusion Both of Erlotinb and pertuzumab have inhibitory effect on xenograft models of human non-small cell lung cancer and breast cancer ,with better effect while combined.
出处
《解剖科学进展》
CAS
2008年第3期277-280,共4页
Progress of Anatomical Sciences
